Dyne Therapeutics to present additional Phase 1/2 trial data
Dyne Therapeutics plans to present additional one-year Phase 1/2 ACHIEVE trial data for z-basivarsen (DYNE-101) in myotonic dystrophy type 1 (DM1) at upcoming medical meetings.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.